BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,830,000 shares, an increase of 2,719.7% from the August 15th total of 64,900 shares. Currently, 84.3% of the company’s stock are short sold. Based on an average daily volume of 793,700 shares, the days-to-cover ratio is presently 2.3 days.

BioCardia Stock Down 1.5 %

BioCardia stock traded down $0.04 during mid-day trading on Thursday, reaching $2.68. 36,830 shares of the company’s stock were exchanged, compared to its average volume of 343,588. The firm has a market capitalization of $4.88 million, a PE ratio of -0.38 and a beta of 1.25. The business’s fifty day simple moving average is $2.90 and its 200 day simple moving average is $4.47. BioCardia has a one year low of $1.96 and a one year high of $23.25.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 1,999.77%. On average, sell-side analysts forecast that BioCardia will post -5.06 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their price target on BioCardia from $4.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, August 16th.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.